Literature DB >> 7927802

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.

F R Noriega1, J Y Wang, G Losonsky, D R Maneval, D M Hone, M M Levine.   

Abstract

We engineered an oral Shigella vaccine prototype that can invade intestinal epithelial cells but cannot undergo extensive intracellular replication or extend to adjacent epithelial cells. Strain CVD 1203, derived from wild-type Shigella flexneri 2a by introducing deletions in chromosomal aroA and invasion plasmid virG, was highly attenuated in the Sereny test. Two 10(9)-CFU orogastric doses (2 weeks apart) stimulated production of secretory immunoglobulin A antibodies to S. flexneri 2a and protected against conjunctival sac challenge with virulent S. flexneri 2a.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927802      PMCID: PMC303242          DOI: 10.1128/iai.62.11.5168-5172.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

2.  Identification of gram-negative aerobic fermentors in a clinical bacteriological laboratory.

Authors:  A A Lindberg; C E Nord; M Hellgren; L Sjöberg
Journal:  Med Microbiol Immunol       Date:  1974-03-22       Impact factor: 3.402

3.  Shigellosis in custodial institutions. 3. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated shigella vaccines.

Authors:  M M Levine; E J Gangarosa; M Werner; G K Morris
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

4.  Shigellosis in custodial institutions. II. Clinical, immunologic and bacteriologic response of institutionalized children to oral attenuated shigella vaccines.

Authors:  M M Levine; H L Dupont; E J Gangarosa; R B Hornick; M J Snyder; J P Libonati; K Glaser; S B Formal
Journal:  Am J Epidemiol       Date:  1972-07       Impact factor: 4.897

5.  Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes.

Authors:  N K Verma; A A Lindberg
Journal:  Vaccine       Date:  1991-01       Impact factor: 3.641

6.  Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin.

Authors:  M L Bernardini; J Mounier; H d'Hauteville; M Coquis-Rondon; P J Sansonetti
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Movement along actin filaments of the perijunctional area and de novo polymerization of cellular actin are required for Shigella flexneri colonization of epithelial Caco-2 cell monolayers.

Authors:  T Vasselon; J Mounier; R Hellio; P J Sansonetti
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile.

Authors:  C Ferreccio; V Prado; A Ojeda; M Cayyazo; P Abrego; L Guers; M M Levine
Journal:  Am J Epidemiol       Date:  1991-09-15       Impact factor: 4.897

9.  Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies.

Authors:  J A Mills; J M Buysse; E V Oaks
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

10.  Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines.

Authors:  J A Robertsson; A A Lindberg; S Hoiseth; B A Stocker
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

View more
  29 in total

Review 1.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 2.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

3.  Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Authors:  S R Klee; B D Tzschaschel; I Fält; A Kärnell; A A Lindberg; K N Timmis; C A Guzmán
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.

Authors:  BreOnna C DeLaine; Tao Wu; Christen L Grassel; Avital Shimanovich; Marcela F Pasetti; Myron M Levine; Eileen M Barry
Journal:  Pathog Dis       Date:  2016-04-21       Impact factor: 3.166

5.  Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Authors:  M L Bernardini; J Arondel; I Martini; A Aidara; P J Sansonetti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity.

Authors:  M T Shata; D M Hone
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Construction of a stable attenuated Shigella sonnei DeltavirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model.

Authors:  A B Hartman; M M Venkatesan
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Deletion of purE attenuates Brucella melitensis 16M for growth in human monocyte-derived macrophages.

Authors:  E S Drazek; H S Houng; R M Crawford; T L Hadfield; D L Hoover; R L Warren
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Systematic annotation and analysis of "virmugens"-virulence factors whose mutants can be used as live attenuated vaccines.

Authors:  Rebecca Racz; Monica Chung; Zuoshuang Xiang; Yongqun He
Journal:  Vaccine       Date:  2012-12-06       Impact factor: 3.641

10.  Unc119 protects from Shigella infection by inhibiting the Abl family kinases.

Authors:  Ramarao Vepachedu; Zunayet Karim; Ojas Patel; Nicholas Goplen; Rafeul Alam
Journal:  PLoS One       Date:  2009-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.